-
1 Comment
Alpa Laboratories Limited is currently in a long term uptrend where the price is trading 14.4% above its 200 day moving average.
From a valuation standpoint, the stock is 85.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.7.
Alpa Laboratories Limited's total revenue rose by 37.5% to $332M since the same quarter in the previous year.
Its net income has increased by 44.6% to $37M since the same quarter in the previous year.
Based on the above factors, Alpa Laboratories Limited gets an overall score of 4/5.
Exchange | NSE |
---|---|
CurrencyCode | INR |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
ISIN | INE385I01010 |
Beta | 0.56 |
---|---|
Target Price | None |
Market Cap | 2B |
PE Ratio | 7.15 |
Dividend Yield | None |
Alpa Laboratories Limited engages in the manufacture and sale of drugs and chemicals in India. It provides formulations that address various therapeutic segments. The company was incorporated in 1988 and is based in Indore, India.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ALPA.NSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025